Cargando…

Risk stratification in heart failure with mild reduced ejection fraction

Heart failure with mid-range ejection fraction represents a heterogeneous and relatively young heart failure category accounting for nearly 20–30% of the overall heart failure population. Due to its complex phenotype, a reliable clinical picture of heart failure with mid-range ejection fraction pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magrì, Damiano, Gallo, Giovanna, Parati, Gianfranco, Cicoira, Mariantonietta, Senni, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Full Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691635/ https://www.ncbi.nlm.nih.gov/pubmed/33238737 http://dx.doi.org/10.1177/2047487320951104

Ejemplares similares

Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction
por: Salvioni, Elisabetta, et al.
Publicado: (2020)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

Comparison among different multiparametric scores for risk stratification in heart failure patients with reduced ejection fraction
por: Corrà, Ugo, et al.
Publicado: (2020)

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
por: Stolfo, Davide, et al.
Publicado: (2023)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Risk stratification according to diastolic function indices in heart failure patients with mildly reduced or reduced ejection fraction
por: Granot, Yoav, et al.
Publicado: (2023)

Haemodynamic validation of the three‐step HFA‐PEFF algorithm to diagnose heart failure with preserved ejection fraction
por: Lanzarone, Ettore, et al.
Publicado: (2023)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
por: Miller, Robert J.H., et al.
Publicado: (2022)

Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2019)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Gori, Mauro, et al.
Publicado: (2021)

Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
por: Talha, Khawaja M., et al.
Publicado: (2022)

Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible
por: Sciatti, Edoardo, et al.
Publicado: (2022)

Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2023)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Sympathetic activation in heart failure with reduced and mildly reduced ejection fraction: the role of aetiology
por: Urbancsek, Réka, et al.
Publicado: (2021)

The Prescription Pattern of Heart Failure Medications in Reduced, Mildly Reduced, and Preserved Ejection Fractions
por: Rastogi, Tripti, et al.
Publicado: (2022)

Clinical application of personalized medicine: heart failure with preserved left ventricular ejection fraction
por: Gori, Mauro, et al.
Publicado: (2020)

Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations
por: Arvanitaki, Alexandra, et al.
Publicado: (2020)

Cardiovascular magnetic resonance phenotyping of heart failure with mildly reduced ejection fraction
por: Brown, Louise A E, et al.
Publicado: (2022)

Machine learning models in heart failure with mildly reduced ejection fraction patients
por: Zhao, Hengli, et al.
Publicado: (2022)

Total 25-Hydroxyvitamin D Is an Independent Marker of Left Ventricular Ejection Fraction in Heart Failure with Reduced and Mildly Reduced Ejection Fraction
por: Szabo, Timea Magdolna, et al.
Publicado: (2023)

Association between class of foundational medication for heart failure and prognosis in heart failure with reduced/mildly reduced ejection fraction
por: Ito, Miyuki, et al.
Publicado: (2022)

Vascular Dysfunction Predicts Future Deterioration of Left Ventricular Ejection Fraction in Patients with Heart Failure with Mildly Reduced Ejection Fraction
por: Kishimoto, Shinji, et al.
Publicado: (2021)

Independent predictors of developing pulmonary hypertension in heart failure with reduced versus preserved ejection fraction
por: Roushdy, Alaa, et al.
Publicado: (2017)

Long-Term Outcomes of Heart Failure Patients With Preserved, Mildly Reduced, and Reduced Ejection Fraction
por: Nagata, Takuya, et al.
Publicado: (2023)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
por: Senni, Michele, et al.
Publicado: (2022)

Sex differences in patients with heart failure and mildly reduced left ventricular ejection fraction
por: Liu, Zhican, et al.
Publicado: (2023)

Efficacy of guideline‐directed medical treatment in heart failure with mildly reduced ejection fraction
por: Zhang, Xinxin, et al.
Publicado: (2022)

Machine Learning for Mortality Prediction in Patients With Heart Failure With Mildly Reduced Ejection Fraction
por: Tian, Pengchao, et al.
Publicado: (2023)

Heart Failure Across the Range of Mildly Reduced and Preserved Ejection Fraction in the United States
por: Greene, Stephen J., et al.
Publicado: (2023)

Management of heart failure with reduced ejection fraction
por: Haydock, Paul M, et al.
Publicado: (2022)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction
por: Stolfo, Davide, et al.
Publicado: (2022)

Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis
por: Burnett, Heather, et al.
Publicado: (2017)

Proteomic profiling of epicardial fat in heart failure with preserved versus reduced and mildly reduced ejection fraction
por: Gao, Qian, et al.
Publicado: (2023)

The Role of Congestion Biomarkers in Heart Failure with Reduced Ejection Fraction
por: Correale, Michele, et al.
Publicado: (2023)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction
por: Straw, Sam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qns16gjf40a85di14fk9gp6l13